Sertraline and Citalopram Actions on Gut Barrier Function

Area of Science:

• Gastroenterology
• Pharmacology
• Immunology

Background:

• Intestinal barrier disruption is implicated in various diseases, with luminal content translocation potentially triggering inflammation.
• Toll-like receptor (TLR) signaling influences epithelial permeability, making TLR inhibition a potential strategy for maintaining gut barrier integrity.
• Selective serotonin reuptake inhibitors (SSRIs) like sertraline and citalopram inhibit TLR-3, but their direct impact on the gut mucosa barrier is not well understood.

Purpose of the Study:

• To investigate the effects of sertraline and citalopram on intestinal barrier integrity.
• To evaluate the potential of these antidepressants in protecting the gut mucosa barrier.

Main Methods:

• Ex vivo studies using isolated intestinal tissue to assess changes in permeability.
• In vivo studies in a rat model with a disrupted gut barrier induced by a low protein diet.
• Measurement of transepithelial electrical resistance and phospho-IRF3 protein levels as markers of barrier function and TLR-3 activation.

Main Results:

• Sertraline increased transepithelial electrical resistance in rat colon ex vivo and in vivo.
• Citalopram, but not sertraline, prevented increased phospho-IRF3 protein in the ileum of rats on a low protein diet, indicating TLR-3 inhibition.
• Neither drug affected animal behavior, including locomotion, anxiety, or stress-induced defecation.

Conclusions:

• Sertraline demonstrates potential as a therapeutic agent to protect intestinal barrier function in conditions involving gut epithelial disruption.
• Further investigation into sertraline's role in managing gastrointestinal and systemic inflammatory disorders is warranted.